NSCLC Immunotherapy Sequencing After Short-Course Platinum Doublet
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need to enhance the efficacy of anti-PD-1 or anti-PD-L1 therapies for treating tumors, particularly in non-small cell lung cancer (NSCLC), as existing immunotherapies may not fully overcome tumor evasion mechanisms and require optimization of treatment duration and combination with other agents.
Innovation Solution
A method involving a chemotherapy induction phase of less than standard duration followed by administration of anti-PD-1 or anti-PD-L1 antibodies, optionally with anti-CTLA-4 antibodies, to enhance treatment efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If standard duration chemotherapy is administered, then tumor response is achieved, but treatment duration and toxicity exposure are increased
Solution Approach 1:
The patent applies preliminary action by administering a reduced duration of chemotherapy (induction phase) before transitioning to immunotherapy. This preliminary chemotherapy exposure prepares the tumor microenvironment and immune system for subsequent immunotherapy, achieving effective tumor response while reducing overall chemotherapy exposure time and toxicity
Solution Approach 2:
The patent implements dynamics by dynamically adjusting the treatment regimen based on treatment phase. The protocol transitions from chemotherapy-only induction to combination immunotherapy in the maintenance phase, optimizing treatment duration by adapting therapy intensity and type to the patient's response and tumor characteristics over time
2Ease of operation
If immunotherapy is administered alone, then treatment simplicity is maintained, but efficacy is insufficient to overcome tumor evasion mechanisms
Solution Approach 1:
The patent applies merging by combining chemotherapy and immunotherapy (anti-PD-1 or anti-PD-L1 antibodies) into a unified treatment protocol. The induction phase uses chemotherapy to reduce tumor burden and modulate the microenvironment, while the maintenance phase combines immunotherapy to sustain response, thereby overcoming tumor evasion mechanisms that would resist single-agent immunotherapy
Solution Approach 2:
The patent implements segmentation by dividing the treatment into distinct phases: an induction phase with chemotherapy and an maintenance phase with immunotherapy. This segmentation allows optimization of each phase's purpose - chemotherapy for rapid initial response and immunotherapy for sustained long-term control - while maintaining operational clarity through phase-based management
3Reliability
If chemotherapy duration is extended, then tumor control is improved, but toxicity and quality of life impact increase
Solution Approach 1:
The patent applies parameter changes by modifying the chemotherapy duration parameter from standard prolonged administration to a reduced induction phase. This parameter change maintains effective tumor control through the induction phase while reducing cumulative chemotherapy toxicity, as the subsequent maintenance phase relies on immunotherapy rather than continued chemotherapy
Data Source
AI summary
The disclosure provides a method for treating a subject afflicted with a tumor, e.g., derived from a non-small cell lung cancer (NSCLC), comprising administering to the subject a combination of a (a) chemotherapy, (b) an anti-PD-1 antibody or an anti-PD-L1 antibody, and (c) an anti-CTLA-4 antibody, wherein the chemotherapy is administered for a period of time that is less than the standard.